Overview

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Status:
Withdrawn
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
GU Research Network, LLC
Collaborator:
Cancer Research Network of Nebraska/Oncology Associates
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Paclitaxel
Pemetrexed